Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:CGEM NASDAQ:SRPT NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.85-1.3%$11.84$3.98▼$13.52$1.96B1.931.83 million shs1.37 million shsCGEMCullinan Therapeutics$6.99+1.2%$7.70$6.61▼$18.62$412.93M-0.08419,350 shs741,007 shsSRPTSarepta Therapeutics$18.71+1.4%$17.78$10.41▼$138.81$1.83B0.498.85 million shs5.17 million shsTARSTarsus Pharmaceuticals$57.63+0.3%$47.31$28.07▼$59.76$2.43B0.81624,484 shs683,534 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%-2.50%+2.47%+27.35%+195.40%CGEMCullinan Therapeutics0.00%-7.29%-0.57%-23.02%-62.58%SRPTSarepta Therapeutics0.00%+2.80%+4.18%-56.50%-86.12%TARSTarsus Pharmaceuticals0.00%-1.62%+20.19%+31.22%+98.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.85-1.3%$11.84$3.98▼$13.52$1.96B1.931.83 million shs1.37 million shsCGEMCullinan Therapeutics$6.99+1.2%$7.70$6.61▼$18.62$412.93M-0.08419,350 shs741,007 shsSRPTSarepta Therapeutics$18.71+1.4%$17.78$10.41▼$138.81$1.83B0.498.85 million shs5.17 million shsTARSTarsus Pharmaceuticals$57.63+0.3%$47.31$28.07▼$59.76$2.43B0.81624,484 shs683,534 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%-2.50%+2.47%+27.35%+195.40%CGEMCullinan Therapeutics0.00%-7.29%-0.57%-23.02%-62.58%SRPTSarepta Therapeutics0.00%+2.80%+4.18%-56.50%-86.12%TARSTarsus Pharmaceuticals0.00%-1.62%+20.19%+31.22%+98.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.88Moderate Buy$12.38-3.70% DownsideCGEMCullinan Therapeutics 3.00Buy$26.80283.40% UpsideSRPTSarepta Therapeutics 2.07Hold$43.50132.50% UpsideTARSTarsus Pharmaceuticals 2.83Moderate Buy$66.6715.68% UpsideCurrent Analyst Ratings BreakdownLatest CGEM, ADPT, SRPT, and TARS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell8/21/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$24.008/20/2025SRPTSarepta TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$17.008/18/2025CGEMCullinan TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$35.00 ➝ $28.008/15/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$12.008/7/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$19.008/7/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$48.00 ➝ $50.008/6/2025ADPTAdaptive BiotechnologiesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $14.008/6/2025ADPTAdaptive BiotechnologiesTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $15.008/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$13.00 ➝ $15.007/29/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$22.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M10.93N/AN/A$1.37 per share9.38CGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/ASRPTSarepta Therapeutics$1.90B0.96$2.44 per share7.68$15.99 per share1.17TARSTarsus Pharmaceuticals$182.95M13.30N/AN/A$5.87 per share9.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.82N/AN/AN/A-59.07%-60.93%-23.03%11/6/2025 (Estimated)CGEMCullinan Therapeutics-$167.38M-$3.23N/AN/AN/AN/A-36.56%-34.82%11/6/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A1.71N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)TARSTarsus Pharmaceuticals-$115.55M-$2.33N/AN/AN/A-31.13%-32.36%-21.04%11/12/2025 (Estimated)Latest CGEM, ADPT, SRPT, and TARS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CGEMCullinan Therapeutics-$0.83-$1.07-$0.24-$1.07N/AN/A8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 million8/6/2025Q2 2025TARSTarsus Pharmaceuticals-$0.33-$0.48-$0.15-$0.48$95.81 million$102.66 million8/5/2025Q2 2025ADPTAdaptive Biotechnologies-$0.24-$0.17+$0.07-$0.17$49.40 million$49.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.842.75CGEMCullinan TherapeuticsN/A9.839.83SRPTSarepta Therapeutics0.842.891.81TARSTarsus Pharmaceuticals0.225.265.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%CGEMCullinan Therapeutics86.31%SRPTSarepta Therapeutics86.68%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%CGEMCullinan Therapeutics7.16%SRPTSarepta Therapeutics7.60%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790152.27 million142.53 millionOptionableCGEMCullinan Therapeutics3059.07 million54.84 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableTARSTarsus Pharmaceuticals5042.21 million38.43 millionOptionableCGEM, ADPT, SRPT, and TARS HeadlinesRecent News About These CompaniesCormorant Asset Management LP Sells 100,000 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 6 at 7:45 AM | marketbeat.comCutter Capital Management LP Acquires 92,500 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 6 at 7:35 AM | marketbeat.comAlly Bridge Group NY LLC Sells 45,212 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 5 at 6:53 AM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Time to Buy?September 4 at 12:32 PM | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Frazier Life Sciences Management L.P.September 4 at 6:50 AM | marketbeat.comNorthern Trust Corp Grows Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 3, 2025 | marketbeat.comGhisallo Capital Management LLC Acquires New Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 2, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Position Increased by Paradigm Biocapital Advisors LPSeptember 2, 2025 | marketbeat.com5,284 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by FORA Capital LLCSeptember 1, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Invests $36.88 Million in Tarsus Pharmaceuticals, Inc. $TARSAugust 31, 2025 | marketbeat.comWellington Management Group LLP Trims Stock Position in Tarsus Pharmaceuticals, Inc. $TARSAugust 31, 2025 | marketbeat.comJump Financial LLC Takes $2.51 Million Position in Tarsus Pharmaceuticals, Inc. $TARSAugust 29, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.com16,020 Shares in Tarsus Pharmaceuticals, Inc. $TARS Acquired by Quantbot Technologies LPAugust 27, 2025 | marketbeat.com3 Biotech Catalysts Present Major Opportunity (TARS)...August 25, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Aberdeen Group plcAugust 24, 2025 | marketbeat.comNuveen LLC Purchases New Shares in Tarsus Pharmaceuticals, Inc. $TARSAugust 24, 2025 | marketbeat.comVanguard Group Inc. Increases Stock Position in Tarsus Pharmaceuticals, Inc. $TARSAugust 24, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Atika Capital Management LLCAugust 23, 2025 | marketbeat.comRussell Investments Group Ltd. Acquires 132,450 Shares of Tarsus Pharmaceuticals, Inc. $TARSAugust 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Brutal 2025 for Sarepta—Analysts Still Call for 179% UpsideBy Leo Miller | August 12, 2025CGEM, ADPT, SRPT, and TARS Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$12.85 -0.17 (-1.31%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$12.89 +0.04 (+0.31%) As of 09/5/2025 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Cullinan Therapeutics NASDAQ:CGEM$6.99 +0.08 (+1.16%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.13 +0.14 (+2.02%) As of 09/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$18.71 +0.25 (+1.35%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$18.63 -0.08 (-0.41%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Tarsus Pharmaceuticals NASDAQ:TARS$57.63 +0.20 (+0.35%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$57.62 -0.01 (-0.01%) As of 09/5/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
